7 results about "Tauroursodesoxycholic acid" patented technology

Provided are pharmaceutical compositions comprising a combination therapy having therapeutically effective amounts of sodium 4-phenyIbutylate and tauroursodeoxycholic acid for the treatment of an ocular condition in a subject. Also provided herein are methods using the combination therapy, and a pharmaceutical composition thereof, for preventing or treating an ocular condition in a subject.

The invention provides bile acid for improving microgravity-induced glucose metabolism disorder and application of the bile acid, and belongs to the technical field of medicines. According to the invention, tauroursodeoxycholic acid (TUDCA) is utilized to effectively reduce the blood glucose level of a microgravity environment model mouse, improve the liver glucose metabolism function and inflammation state of the microgravity environment model mouse, and reduce the serum cholesterol level of the model mouse; a technical scheme which is high in safety and clear in targeting and has application potential is provided for intervention of metabolic abnormalities in the microgravity environment, and an experimental foundation is laid for development of related functional products or protective preparations.

The invention relates to the field of biology, in particular to application of tauroursodeoxycholic acid in preparation of a medicine for promoting function maturation of islet organs. The specific effect of tauroursodeoxycholic acid in promoting functional maturation of iPSC-derived islet-like organs is found and verified for the first time, and a brand new treatment thought is represented. The beta cell functional gene expression and glucose stimulation response capability of the sc-islet can be remarkably improved only by performing TUDCA treatment for 96 hours, and the function maturation period is greatly shortened. The obvious effect can be achieved by adopting the low-dose TUDCA with the concentration of 25-100 ng / mL, the cost is reduced, and the potential toxicity risk is reduced. Key indexes (functional gene expression and glucose response) of beta cell maturation are directly targeted, and a high-quality cell model is provided for research and treatment of diabetes mellitus.

This invention discloses the application of tauroursodeoxycholic acid (TUDCA) in inhibiting α-glucosidase activity, belonging to the field of biotechnology. The invention utilizes porcine bile salts and bear bile powder for in vitro α-glucosidase inhibition experiments, performs molecular docking simulations on the components, and screens multiple bile acids for α-glucosidase inhibition, ultimately identifying TUDCA as the experimental material. Furthermore, in vivo and in vitro experiments were conducted to study the effects of TUDCA on α-glucosidase, revealing that TUDCA can significantly inhibit α-glucosidase activity and alleviate insulin resistance, classifying it as an anti-competitive inhibitor. This invention provides a novel raw material for inhibiting α-glucosidase activity, which can be applied to α-glucosidase activity inhibitors or drugs for alleviating insulin resistance.

The invention provides application of tauroursodeoxycholate in prevention or treatment of mitochondrial encephalopathy, and belongs to the technical field of medicine. The core of the invention lies in that the pathological mechanism of the mitochondrial encephalopathy is coped with by utilizing multiple biological effects of the TUDCA. In-vivo and in-vitro experiments find that after a cKO mouse is treated by TUDCA, the expression of an endoplasmic reticulum stress marker Atf4 and fatty acid synthase (Fasn) in the mouse can be remarkably reduced, and abnormal accumulation of lipid is reduced, so that the metabolic state of cells is improved. In animal models, treatment with TUDCA not only alleviates dyskinesia, but also promotes the neurogenesis process and extends the survival time of mice.

The invention relates to the technical field of genomics and metabonomics, in particular to a substance for relieving intestinal injury of crisp tilapia and an application effect analysis method of the substance. According to the invention, the tauroursodeoxycholic acid (TUDCA) is applied to relieving intestinal inflammation damage caused by feed embrittlement of the crisp tilapia for the first time, and intestinal inflammation is relieved. By establishing a three-dimensional evaluation system of'intestinal histomorphology + metabonomics + metagenomics', the relieving effect of TUDCA on intestinal inflammation is systematically quantified. Through combined analysis of intestinal metabolome and metagenome, a'microorganism-host interaction 'health judgment model is constructed, and the maintenance of the quality of fish meat after inflammation is relieved is verified through muscle texture parameters, so that a'repair-evaluation-quality maintenance' closed-loop technical scheme is formed.

The present application relates to the fields of medicine, biotechnology and clinical critical medicine, and specifically discloses application of tauroursodeoxycholic acid or pharmaceutically acceptable salt, derivative or precursor thereof in preparation of a drug for improving intestinal barrier function and prognosis of a patient with sepsis. The present application discloses for the first time a molecular mechanism of TUDCA for protecting intestinal barrier function by regulating a signal axis of intestinal flora-Coriolic acids-PPARbeta-ILK, and TUDCA significantly improves the integrity of intestinal barrier by restoring intestinal flora balance, inhibiting generation of harmful metabolite Coriolic acids and activating the PPARbeta-ILK signal pathway. In the treatment of sepsis, TUDCA not only helps to repair the intestinal barrier, but also can improve the clinical prognosis of the patient, reduce the level of systemic inflammation, alleviate multiple organ failure caused by sepsis, and improve the survival rate, thereby providing a new strategy for the treatment of sepsis.